The COVID-19 pandemic has affected pharmaceutical companies’ abilities to conduct clinical trials and drug development programmes safely.

GlobalData has conducted a survey to identify how the COVID-19 pandemic affected clinical trial planning for companies in the first and third quarters of 2020.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

An analysis of the responses reveals that the companies believe that the pandemic will affect patient recruitment for the planning of trials as expressed by30% of the respondents in Q1, although the percentage dropped to 26% in Q3.

Investigator recruitment and supply of clinical trial materials were considered as the next major concerns by 17% of the respondents each in Q1, which dropped to 12% and 15%, respectively, in Q3.

Clinical trial disruptions Q1 vs Q3

Effect of coronavirus on clinical trial planning Q1 vs Q3

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cancelling or postponing trials was being considered by approximately 14% of the respondents in Q1, which increased to 17% in Q3.

The concerns regarding regulatory resources being stretched decreased from 10% in Q1 to 8% in Q3, while the number of companies who are considering changing trial venues jumped from 5% in Q1 to 11% in Q3.

In Q1, 4% of the respondents said that they do not plan to conduct clinical trials in the next two years, which increased to 5% in Q3.

Companies acknowledging that the COVID-19 pandemic will not affect clinical trials increased from 4% in Q1 to 7% in Q3.

The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey conducted between 07 July and 30 July 2020.